John M Vierling1, Masoud Mokhtarani2, Robert S Brown3, Parvez Mantry4, Don C Rockey5, Marwan Ghabril6, Richard Rowell2, Marzena Jurek2, Dion F Coakley2, Bruce F Scharschmidt7. 1. Baylor College of Medicine, Houston, Texas. 2. Horizon Therapeutics, Inc, Lake Forest, Illinois. 3. Columbia University Medical Center, New York, New York. 4. Liver Institute at Methodist Dallas Medical Center, Dallas, Texas. 5. Medical University of South Carolina, Charleston, South Carolina. 6. Indiana University, Indianapolis, Indiana. 7. Horizon Therapeutics, Inc, Lake Forest, Illinois. Electronic address: bruce.scharschmidt@gmail.com.
Abstract
BACKGROUND & AIMS: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). METHODS: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) orplacebofor 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. RESULTS: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. CONCLUSIONS: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.
RCT Entities:
BACKGROUND & AIMS: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). METHODS: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. RESULTS: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. CONCLUSIONS: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.
Authors: C S Landis; M Ghabril; V Rustgi; A M Di Bisceglie; B Maliakkal; D C Rockey; J M Vierling; J Bajaj; R Rowell; M Santoro; A Enriquez; M Jurek; M Mokhtarani; D F Coakley; B F Scharschmidt Journal: Dig Dis Sci Date: 2016-01-19 Impact factor: 3.199
Authors: David E Fried; Ralph E Watson; Simon C Robson; Brian D Gulbransen Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-08-24 Impact factor: 4.052
Authors: Javier De Las Heras; Luis Aldámiz-Echevarría; María-Luz Martínez-Chantar; Teresa C Delgado Journal: Expert Opin Drug Metab Toxicol Date: 2016-11-28 Impact factor: 4.481
Authors: Virginia Gutiérrez-de-Juan; Sergio López de Davalillo; David Fernández-Ramos; Lucía Barbier-Torres; Imanol Zubiete-Franco; Pablo Fernández-Tussy; Jorge Simon; Fernando Lopitz-Otsoa; Javier de Las Heras; Paula Iruzubieta; María Teresa Arias-Loste; Erica Villa; Javier Crespo; Raúl Andrade; M Isabel Lucena; Marta Varela-Rey; Shelly C Lu; José M Mato; Teresa Cardoso Delgado; María-Luz Martínez-Chantar Journal: PLoS One Date: 2017-03-20 Impact factor: 3.240